Alison L Hannah
Overview
Explore the profile of Alison L Hannah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1985
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tripathy D, Tolaney S, Seidman A, Anders C, Ibrahim N, Rugo H, et al.
JAMA Oncol
. 2022 May;
8(7):1047-1052.
PMID: 35552364
Importance: Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the...
2.
Naing A, Thistlethwaite F, de Vries E, Eskens F, Uboha N, Ott P, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34301809
Background: Probody therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing 'off-tumor' toxicity. We report...
3.
Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon J, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4521-4530.
PMID: 34083236
Purpose: PROCLAIM-CX-2029 is a phase I first-in-human study of CX-2029, a Probody-drug conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid tumors. Although the transferrin receptor is highly...
4.
Diab A, Tannir N, Bentebibel S, Hwu P, Papadimitrakopoulou V, Haymaker C, et al.
Cancer Discov
. 2020 May;
10(8):1158-1173.
PMID: 32439653
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, renal cell carcinoma,...
5.
Tripathy D, Tolaney S, Seidman A, Anders C, Ibrahim N, Rugo H, et al.
Future Oncol
. 2019 May;
15(19):2211-2225.
PMID: 31074641
The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed...
6.
Turner N, Telli M, Rugo H, Mailliez A, Ettl J, Grischke E, et al.
Clin Cancer Res
. 2018 Dec;
25(9):2717-2724.
PMID: 30563931
Purpose: To assess talazoparib activity in germline mutation carriers with advanced breast cancer. Patients And Methods: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in...
7.
Litton J, Rugo H, Ettl J, Hurvitz S, Goncalves A, Lee K, et al.
N Engl J Med
. 2018 Aug;
379(8):753-763.
PMID: 30110579
Background: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). Methods: We conducted a randomized,...
8.
Lenz H, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L, et al.
Cancer Chemother Pharmacol
. 2017 Oct;
80(6):1161-1169.
PMID: 29043412
Purpose: Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line...
9.
Cortes J, Rugo H, Awada A, Twelves C, Perez E, Im S, et al.
Breast Cancer Res Treat
. 2017 Sep;
166(1):327-328.
PMID: 28884461
No abstract available.
10.
Cortes J, Rugo H, Awada A, Twelves C, Perez E, Im S, et al.
Breast Cancer Res Treat
. 2017 Jun;
165(2):329-341.
PMID: 28612225
Purpose: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to...